Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
We are recruiting women with hypothalamic amenorrhea or Idiopathic Hypogonadotropic
Hypogonadism. Kisspeptin will be administered subcutaneously (SC) for 2-weeks in a pulsatile
fashion. Ultrasound monitoring of ovarian follicular growth and frequent blood sampling (q10
min for up to 2hr) will be performed to assess the physiologic response to kisspeptin over
time.